Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NUTRAMAX TO BUY PRIVATE-LABEL COUGH DROP MANUFACTURER POWERS PHARMACEUTICAL

This article was originally published in The Tan Sheet

Executive Summary

NUTRAMAX TO BUY PRIVATE-LABEL COUGH DROP MANUFACTURER POWERS PHARMACEUTICAL underan agreement announced Nov. 16. NutraMax Products noted that Brockton, Mass.-based Powers is the "nation's leading manufacturer and distributor of private-label cough drops and throat lozenges, and it also manufactures cough drops on a contract basis for a major national brand." Powers reported sales of almost $ 16 mil. in the fiscal year ended June 26. The acquisition of Powers "broadens our product line, enhances the company's position as an important private-label supplier to our retail customers, and reduces the company's reliance on any one product," NutraMax President and CEO Donald Lepone stated. Lepone added that "with the sales and marketing expertise of NutraMax, we anticipate being able to significantly increase sales of Powers' private-label products." Completion of the deal is expected to occur "shortly" and is "contingent upon certain conditions." Terms of the deal were not disclosed. The purchase of Powers is the third acquisition this year for NutraMax, a Gloucester, Mass.-based private-label manufacturer and marketer of such products as douches, ready-to-use enemas and pediatric electrolyte oral maintenance solutions. In March, the firm acquired private-label eye care products firm Optopics ("The Tan Sheet" March 15, p. 12). NutraMax also is planning a late fall introduction of private-label clotrimazole cream and inserts following an agreement with an undisclosed supplier ("The Tan Sheet" July 12, In Brief). Separately, NutraMax expects to begin shipments of bubble gum- flavored oral maintenance solution to its private-label customers in January. The new flavor is a generic copy of Abbott Labs' bubble gum-flavored Pedialyte oral maintenance solution and follows UBI's recent launch of a bubble gum-flavored version of its oral maintenance solution, Naturalyte ("The Tan Sheet" Oct. 18, In Brief). Powers recently bolstered its throat-drop line with the addition of 30-count bags of sugar-free cough suppressant drops in menthol and cherry flavors, joining the growing market of sugar-free throat lozenges (Hershey's Luden's sugar-free throat drops and F&F Labs' Sugar-Free All-Herbal Cough & Throat Drops). Powers also has begun rolling out its throat lozenges in 16-count blister packs similar to SmithKline Beecham's 'Ice in cherry, citrus and menthol flavors.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel